Peter H. Griffith - Nov 1, 2021 Form 4 Insider Report for AMGEN INC (AMGN)

Role: EVP & CFO
Signature: /s/ Peter H. Griffith
Stock symbol: AMGN
Transactions as of: Nov 1, 2021
Transactions value $: -$550,747
Form type: 4
Date filed: 11/3/2021, 07:22 PM
Next filing: May 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Tax liability	-$551K	-2.66K	-10.09%	$206.97	23.7K	Nov 1, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares include the following RSUs granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2	These shares include 930 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

Content

These shares include the following RSUs granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

These shares include 930 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.